Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®.
A timing-of-birth effect on multiple sclerosis clinical phenotype.
Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice.
Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects.
Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis.
Japanese macaque encephalomyelitis: a spontaneous multiple sclerosis-like disease in a nonhuman primate.
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative--Fumapharm/Biogen Idec.
Direct immunomodulatory influence of IFN-β on human astrocytoma cells.
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with MS.
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Gender-specific expression of beta1 integrin of VLA-4 in myelin basic protein-primed T cells: implications for gender bias in multiple sclerosis.
An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation.
The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease.
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.
Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls.
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
FP187 – Oral Immunomodulatory Dimethyl Fumarate (DMF)
Zist Daru, ZIFERON
Mycophenolate mofetil for relapsing-remitting multiple sclerosis.
Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.
Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex.
Viral triggers of multiple sclerosis.

Pages